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Effect of rituximab treatment on T and B cell
subsets in lymph node biopsies of patients
with rheumatoid arthritis
Tamara H. Ramwadhdoebe1,2, Lisa G. M. van Baarsen1,2, Maria J. H. Boumans1,
Stefan T. G. Bruijnen 3, Mary Safy1, Ferco H. Berger4, Johanna F. Semmelink1,2,
Conny J. van der Laken3, Danielle M. Gerlag1,5, Rogier M. Thurlings1,a and
Paul P. Tak1,6,7,*
Abstract
Objectives. The exact underlying mechanism of rituximab treatment in patients with RA is poorly defined and know-
ledge about the effect of B cell depletion on immune cells in secondary lymphoid organs is lacking. We analysed
lymphoid tissue responses to rituximab in RA patients.
Methods. Fourteen RA patients received 2 1000 mg rituximab intravenously, and lymph node (LN) biopsies were
obtained before and 4 weeks after the first infusion. Tissues were examined by flow cytometry, immunohistochemistry
and quantitative PCR. LN biopsies from five healthy individuals (HC) served as controls.
Results. LN biopsies of RA patients showed increased frequencies of CD21+CD23+IgDhighIgMvariable follicular B cells
and CD3+CD25+CD69+ early activated, tissue resident T cells when compared with HCs. After treatment, there was
incomplete depletion of LN B cells. There was a significant decrease in CD27IgD+ naı¨ve B cells, and CD27+IgD+
unswitched memory B cells including the CD27+IgD+IgM+ subset and follicular B cells. Strikingly, CD27+IgD switched
memory B cells persisted in LN biopsies after rituximab treatment. In the T cell compartment, a significant decrease was
observed in the frequency of early activated, tissue resident T cells after rituximab treatment, but late activated T cells
persisted. B cell proliferation inducing cytokine IL-21 was higher expressed in LN biopsies of RA patients compared with
HC and expression was not affected by rituximab treatment.
Conclusion. Rituximab does not cure RA, possibly due to persistence of switched memory B cells in lymphoid tissues
suggesting that factors promoting B cell survival and differentiation need to be additionally targeted.
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Rheumatology key messages
. Rituximab treatment improves RA, in part because B cell depletion results in decreased T cell activation.
. Rituximab does not cure RA, possibly due to persistent switched memory B cells in lymphoid tissues.
. An RA cure may perhaps only be achieved if B cell survival and differentiation factors are also targeted.
Introduction
RA is an immune-mediated inflammatory disease affect-
ing 1% of the population and is characterized by synovial
inflammation leading to destruction of cartilage and bone.
Autoreactive B cells are thought to be pivotal in the aeti-
ology of RA because of its association with autoantibodies
such as IgM-RF and/or ACPA, which can precede the
clinical onset of the disease by many years [1, 2]. In add-
ition, the inflamed synovial tissue contains expanded B
cell clones [3] and ectopic germinal centre-like structures
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[4]. Also, the majority of RA patients show clinical benefit
upon treatment with the B cell depleting anti-CD20 anti-
body rituximab [57]. However, rituximab treatment does
not target antibody-producing plasma cells and does not
cure RA as additional treatment is required upon B cell
recovery.
Administration of rituximab results in a rapid, almost
complete depletion of CD20 positive B cells in peripheral
blood but only partial depletion in synovial tissue and
bone marrow [813]. The relative resistance of B cells to
the effects of rituximab in tissues may be related to sus-
tained expression of protective factors such as B cell acti-
vating factor (BAFF, also called B lymphocyte stimulator),
complement inhibitors CD55 (decay-accelerating factor)
and CD59, or increased expression of receptors for B
cell survival, such as BAFF receptor (BAFF-R) and trans-
membrane activator and CAML interactor (TACI).
The underlying mechanisms of anti-CD20 antibody
therapy are still poorly defined, and it is not known why
this treatment may result in long-lasting improvement but
not in cure. We found that memory B cells infiltrate the
inflamed synovial tissues of only a proportion of RA pa-
tients and that the extent of synovial B cell depletion
varied between patients [11]. Presence or change in syn-
ovial B cells did not predict clinical response to treatment.
We hypothesized that the variable clinical response and
resistance to rituximab is caused by variable depletion
and persistence of autoreactive memory B cells in sec-
ondary lymphoid tissue where autoantigen presentation
and differentiation of these cells are likely to occur.
Therefore, we investigated the effect of rituximab therapy
on immune cells in lymph node (LN) biopsies of RA
patients.
Methods
Patients
Fourteen RA patients were included in the study. All pa-
tients were diagnosed according to the ACR 1987 classifi-
cation criteria for RA [14] and had active disease defined by
a DAS evaluated in 28 joints (DAS28) >3.2. Stable treat-
ment for at least 2 weeks with DMARDs, oral corticoster-
oids up to 10 mg daily and NSAIDs was permitted. Patients
had previously failed treatment with at least one anti-TNF
agent, defined as inadequate response or intolerance. Anti-
TNF treatment was discontinued at least 4 weeks before
start of treatment with rituximab. For comparison, five
healthy individuals who were IgM-RF and ACPA negative
were included. The study was approved by the Medical
Ethics Committee of the AMC/University of Amsterdam
and all patients gave written informed consent.
Study design
Patients were treated with intravenous infusions of
1000 mg of rituximab on day 1 and day 15 as previously
described [11]. Premedication with methylprednisolone
was omitted so as to be able to study the specific effects
of rituximab. LN tissue was obtained as described previ-
ously [15] before and 4 weeks after the first infusion with
rituximab. Immediately after collection biopsies were pro-
cessed for flow cytometry analysis, snap-frozen en bloc in
Tissue-Tek OCT compound (Miles, Elkhart, IN, USA) for
immunohistochemistry analysis or snap frozen for RNA
isolation. Clinical assessment was performed at day 0,
and after 2, 4, 8, 12, 16, 20 and 24 weeks after start of
treatment, including assessment of DAS28, CRP levels
and ESR.
Flow cytometry analysis of peripheral blood
Peripheral blood was drawn before and 4 weeks after the
start of rituximab treatment to determine ACPA and IgM-RF
levels. B cell frequencies were determined by highly sensi-
tive B cell analysis using flow cytometry [16]. B cells were
defined as CD19+CD22+ double positive cells. Complete
depletion of B cells was defined as <0.0001109/L.
Flow cytometry analysis of lymph node tissue
LN tissue was put through a 70 mm (BD Falcon, San Jose,
CA) cell strainer to obtain a single cell suspension. Cells
were washed with PBS containing 0.01% NaN3 and 0.5%
BSA and stained for 30 min at 4C with directly labelled
antibodies: CD45 PercP-Cy5.5, CD19 Alexa-700, CD27
APC-H7, IgD Pe-Cy7, CD20 PE, IgM FITC, CD69 PE,
CD69 PerCP, CD21 APC, CD23 PE, CD25 APC, CD267
PE, BAFF-R FITC, CD16 Percp-Cy5.5, CD56 PE, CD55
PE, CD59 FITC (BD Biosciences, Breda, the
Netherlands), HLA-DR Alexa-700 (eBioscience, Vienna,
Austria), CD3 FITC (Sanquin, Amsterdam, the
Netherlands). After incubation cells were washed and im-
mediately analysed on a FACS CANTO II (BD
Biosciences). To enable the measurement of different B
cell subsets, a seven-colour FACS panel was set-up using
antibodies against CD19, IgD, IgM, CD27, CD21, CD23
and CD45 (for normalization). Data were analysed using
FlowJo software (Treestar, Ashland, OR, USA) and pre-
sented as frequencies, absolute numbers relative to
100 000 CD45+ lymphocytes or geometric mean fluores-
cence intensity (normalized on negative populations).
Immunohistochemical analysis of lymphoid tissue
sections
Sections (5 mm each) were cut and mounted on StarFrost
adhesive glass slides (Knittelgla¨ser, Braunschweig,
Germany). Sealed slides were stored at 80C until fur-
ther use. LN tissue sections were stained using mouse
monoclonal antibodies against T cells (anti-CD3, clone
SK7; Becton Dickinson, Breda, the Netherlands), B cells
(anti-CD22, clone RFB4; Millipore, Amsterdam, the
Netherlands) and plasma cells (anti-CD138, clone MI15;
Dako, Heverlee, Belgium).
Staining was performed using a three-step immunoper-
oxidase method to detect bound anti-CD138 antibodies, as
described previously [17]. For anti-CD3 and anti-CD22, we
used a two-step immunoperoxidase method with a sec-
ondary polymer—horseradish peroxidase—conjugated
anti-mouse antibody (EnVision+ System; Dako). As a nega-
tive control, irrelevant isotype-matched immunoglobulins,
instead of the primary antibody, were applied to the
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sections. Staining was analysed by digital image analysis in
a blinded fashion using a Syndia algorithm on a Qwin-
based analysis system (Leica, Cambridge, UK) as
described previously [18]. The number of positive cells
was calculated for each section as the number of positive
cells per square millimetre of tissue.
Quantitative real-time PCR
Total RNA was extracted from LN biopsies using the AllPrep
DNA/RNA mini kit (Qiagen, Venlo, the Netherlands). RNA
(500 ng) was reverse transcribed into cDNA using the
Revertaid H-minus first strand cDNA synthesis kit (Thermo
Fisher Scientific, Amsterdam, the Netherlands) according to
the manufacturer’s instructions. Quantitative real-time PCR
was performed using a Step One Plus detection system
[Thermo Fisher Scientific (Applied Biosystems)] using
Taqman assays [Thermo Fisher Scientific (Applied
Biosystems)] for 18S RNA (Hs99999901_s1) and IL-21
(Hs00222327_m1). Values for each gene were normalized
to the expression level of 18S RNA. An arbitrary cDNA
sample was used on each qPCR plate for normalization
between different experimental runs.
Statistical analysis
Data not normally distributed are presented as medians
with interquartile range. Differences were analysed with
the two-tailed MannWhitney U test. The two-tailed
Wilcoxon signed-rank test for paired data was used to
analyse change after treatment. Correlations were calcu-
lated using a two-tailed Spearman’s rho. All statistical
analyses were performed using Prism software (version
5, GraphPad Software, La Jolla, CA, USA).
Results
Clinical characteristics and clinical response to
rituximab
Patient characteristics and clinical response to treatment
according to the EULAR response criteria are summarized
in Table 1. The mean age between the HCs and RA pa-
tients was significantly different (mean age HCs 36 years,
mean age RA patients 53 years). However, none of the
measured parameters correlated significantly with age.
At baseline, patients had active disease (median
DAS28 = 5.3), and after 24 weeks follow-up, three patients
were classified as non-responders, seven patients were
moderate responders and four patients were good re-
sponders according to EULAR response criteria.
Depletion of B cells in peripheral blood does not
correlate with treatment response
In peripheral blood the frequencies of B cells, before
rituximab treatment, did not correlate with ACPA levels,
IgM-RF levels or DAS28 (Supplementary Fig. S1A, avail-
able at Rheumatology online). Four weeks after the first
rituximab infusion there was complete depletion of periph-
eral blood B cells (cut off <0.0001109/L) in 9 of the 13
patients measured. The extent of peripheral B cell deple-
tion at this time point did not correlate with any of the
baseline disease activity parameters or levels of CRP,
ESR, IgM-RF or ACPA (Supplementary Fig. S1A, available
at Rheumatology online).
Increased frequency of follicular B cells in lymph node
biopsies of RA patients compared with healthy
controls
In LN biopsies, the relative frequencies and absolute num-
bers of CD19+ B cells showed a trend towards an increase
in RA patients (median 21% and 22 662 per 100 000
CD45+ cells) compared with HCs (median 11% and
11 597 per 100 000 CD45+ cells, P= 0.15 and P= 0.09,
respectively) (Fig. 1A and Supplementary Fig. S2, avail-
able at Rheumatology online). Based on CD27 and IgD
expression there was a numerical trend towards increase
in the absolute numbers of unswitched memory
(CD27+IgD+) B cells (median 4124 per 100 000 CD45+
cells) compared with HCs (median 1421 per 100 000
CD45+ cells, P= 0.13) (Supplementary Fig. S2, available
at Rheumatology online). Otherwise, there was no differ-
ence in the relative or absolute frequencies of naı¨ve
(CD27IgD+), unswitched memory (CD27+IgD+), switched
memory (CD27+IgD) or double negative (CD27IgD) B
cells (Fig. 1A and B and Supplementary Fig. S2, available
at Rheumatology online). The relative and absolute fre-
quencies of CD21+CD23+IgDhighIgMvariable B cells, which
represent a subpopulation of follicular B cells that has
been associated with active arthritis in arthritis models
and RA [19], were measured in a subset of patients
TABLE 1 Subjects characteristics and clinical responses
in RA patients
Healthy
controls RA
(n=5) (n=14)
Sex, female, n (%) 4 (80) 12 (86)
Age, mean (S.D.), years 36 (7.5) 53 (13.0)
IgM-RF positive, n (%) 0 (0) 13 (93)
Anti-CCP positive, n (%) 0 (0) 11 (79)
IgM-RF and anti-CCP
both positive, n (%)
0 (0) 10 (71)
IgM-RF and anti-CCP
both negative, n (%)
5 (100) 1 (7)
ESR, median (IQR), mm/h — 21 (12, 32)
CRP, median (IQR), mg/L 0.4 (0.3, 0.7) 4.5 (2.9, 9.8)
DAS28, median (IQR) 0 (0) 5.3 (4.7, 6.0)
Clinical response at 24 weeks
Delta DAS28, median (IQR) 1.6 (0.8, 2.1)
EULAR good, n (%) 4 (29)
EULAR moderate, n (%) 7 (50)
EULAR non, n (%) 3 (21)
Subjects characteristics and clinical responses in RA pa-
tients 24 weeks after the first rituximab infusion.
Categorical variables: n (%); continuous variables (data not
normally distributed): median (IQR). Anti-CCP: anti-citrulli-
nated protein antibodies; DAS28: DAS in 28 joints; IQR:
interquartile range.
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FIG. 1 Lymphoid B cell subsets in healthy individuals and RA patients
LN single cells were analysed using flow cytometry. B cell subsets were analysed in healthy individuals (HC; n= 5), RA
patients (RA; n= 14) and RA patients after two rituximab infusions (RA post-RTX; n= 14). (A) Frequencies of CD19+ B
cells, unswitched memory (CD27+IgD+), switched memory (CD27+IgD), naı¨ve (CD27IgD+) and double negative
(CD27IgD) B cells were determined. (B) Relative distribution between these different B cell subsets present in healthy
and RA patients (before and after RTX) is shown in a bar graph. (C) Frequencies of follicular (CD21+CD23+IgDhigh
IgMvariable) B cells were analysed in healthy individuals (HC; n= 5) and RA patients before and after two rituximab infu-
sions (n= 7). MannWhitney test was used to analyse significant differences in cell subsets between healthy controls and
RA patients (baseline). A Wilcoxon matched-pairs signed rank test was used to analyse significant changes before and
after treatment. *P < 0.05, **P < 0.01, ***P < 0.001. HC: healthy controls; LN: lymph node; RTX: rituximab.
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(n= 7). These were increased in RA patients compared
with HCs (P= 0.02 and P= 0.016) (Fig. 1C and
Supplementary Fig. S2, available at Rheumatology
online). Before as well as after rituximab treatment, the
frequencies of total B cells in peripheral blood of RA pa-
tients did not correlate with the frequency of total B cells
or any specific B cell subset in LN biopsies (data not
shown).
Rituximab treatment mainly depletes naı¨ve and
unswitched memory B cells in lymph node
biopsies but switched memory B cells persist
Four weeks after rituximab treatment, the relative and ab-
solute frequencies of total CD19+ B cells (P= 0.0004) was
significantly decreased but there was still persistence of a
proportion of B cells (median 10% of total lymphocytes
compared with 21% before treatment) (Fig. 1A and
Supplementary Fig. S2, available at Rheumatology
online). With regard to B cell subsets, there was a pro-
nounced decrease in the relative and absolute frequencies
of naı¨ve B cells (P= 0.0006 and P= 0.003) and unswitched
memory B cells (P= 0.001 and P= 0.003). Also,
CD21+CD23+IgDhighIgMvariable follicular B cells decreased
(P= 0.02 and P= 0.03) (Fig. 1A and C and Supplementary
Fig. S2, available at Rheumatology online). However, the
relative and absolute frequencies of switched memory
and double negative B cells were much less altered by
rituximab treatment (switched memory: median 19% and
2359 per 100 000 CD45+ cells before compared with
median 31% and 1290 per 100 000 CD45+ cells after treat-
ment, P= 0.21 and P= 0.074, respectively; double negative
B cells relatively increased: median 23% and 4476 per
100 000 CD45+ cells before compared with median 51%
and 5654 per 100 000 CD45+ cells after treatment, P= 0.01
and P= 0.37, respectively) (Fig. 1A and Supplementary Fig.
S2, available at Rheumatology online). In summary, the
relative distribution of the different B cell subsets after
two rituximab infusions was changed in favour of IgD B
cell populations (Fig. 1B). The changes in different B cell
subsets are summarized in Table 2.
No significant differences in the frequencies of B cell
subsets between the clinical good, moderate and non-re-
sponders could be found at baseline or 4 weeks after
treatment (data not shown). In addition, changes in fre-
quencies of different B cell subsets in lymphoid tissue
between baseline and 4 weeks after rituximab treatment
did not correlate with the change in DAS28 at 24 weeks
(data not shown). Of note, these results need to be inter-
preted with caution as there were only three non-re-
sponders in this exploratory study.
B cell follicular structures and CD138+ plasma cell
numbers in lymph node tissue are unaffected by
rituximab treatment
Since we found limited depletion of lymphoid switched
memory B cells, we analysed if B cell follicles could still
be discerned after treatment using immunohistochemical
staining for CD22. In parallel we analysed the effect of
rituximab on CD138+ plasma cells using immunohisto-
chemistry since surface expression of CD138 to determine
the frequency of plasma cells is challenging to measure by
flow cytometry (Fig. 2A). In line with our flow cytometry
data, CD22+ B cells could still be readily detected after
rituximab treatment, and follicular structures were still pre-
sent. Quantification of the staining confirmed that numbers
of CD22+ cells/mm2 were decreased after rituximab treat-
ment (P< 0.0001). The numbers of CD138+ cells/mm2 were
unaltered after rituximab treatment (Fig. 2B).
TABLE 2 Frequencies of LN immune cells in healthy controls and RA patients
Healthy RA RA post-RTX P
B cells
CD19+ 11.6 (9.727.3) 21.3 (13.832.4) 9.7 (1.314.9) 0.0004
CD27IgD+ 39.3 (21.054.1) 35.2 (23.848.3) 6.8 (3.813.1) 0.0006
CD27+IgD+ 9.0 (7.415.2) 13.4 (6.521.2) 6.0 (1.98.5) 0.0012
CD27IgD 35.5 (18.641.6) 22.7 (16.840.4) 50.8 (41.562.1) 0.0001
CD27+IgD 16.6 (12.130.1) 19.1 (10.231.0) 31.6 (13.141.2) ns
CD21+CD23+IgDhighIgMvar 14.0 (4.3919.95) 44.4 (15.160.0) 1.2 (0.543.05) 0.0156
CD55+ 99.8 (99.2100) 99.7 (99.199.7) 99.1 (97.299.5) ns
CD59+ 84.4 (69.194.3) 84.4 (67.495.7) 81.7 (72.891.0) ns
TACI+ 59.9 (47.570.7) 46.6 (33.261.1) 53.9 (42.067.3) ns
BAFF-R+ 84.6 (77.294.1) 92.9 (88.797.2) 68.1 (46.894.3) 0.03
T cells
CD3+ 81.3 (63.987.4) 75.8 (63.184.5) 79.4 (62.791.6) ns
CD3+CD69+ 8.3 (5.712.7) 24.0 (12.633.0) 15.6 (4.133.2) ns
CD3+CD25+ 22.6 (18.524.4) 28.1 (23.650.3) 22.0 (15.540.6) ns
CD3+CD25+CD69+ 2.2 (1.13.1) 8.4 (3.311.0) 2.7 (0.85.0) 0.03
CD3+HLA-DR+ 30.4 (25.532.6) 21.3 (18.136.0) 27.5 (11.437.7) ns
Data are frequencies of cells (%) presented as median (IQR). A Wilcoxon matched-pairs signed rank test was performed to
analyse significant differences in subsets before vs after RTX treatment. BAFF-R: B cell activating factor receptor; IQR:
interquartile range; LN: lymph node; ns: not significant; RTX: rituximab; TACI: transmembrane activator and CAML interactor.
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Taken together, histology data confirm that not all
lymphoid B cells are depleted after rituximab treatment
and that follicular structures and CD138+ plasma cells
persist in LN tissue.
Complement inhibitor CD55 and BAFF-R are
decreased on persisting B cells
To explore a potential explanation behind the observed
variable responsiveness of LN B cells to rituximab, we
investigated the expression of membrane molecules on
LN B cells potentially involved in resistance to rituximab.
CD20, complement inhibitors CD55 and CD59 as well as
the receptors for B cell survival factor BAFF, BAFF-R and
TACI have all been reported to be associated with a
decreased response to rituximab treatment in various
haematological diseases [2022]. In RA LN biopsies, ex-
pression level of CD20 was comparable between memory
and naı¨ve B cells indicating that there is no difference in
susceptibility to CD20-mediated B cell depletion based on
different CD20 levels (data not shown). CD20 was only
measured at baseline, since rituximab may mask CD20.
The expression levels of CD55 and CD59 (measured by
geometric mean fluorescence intensity) on B cells were
not different in RA patients compared with HCs
(Fig. 3A). CD55 and CD59 expression levels were not cor-
related with B cell subset frequencies. After rituximab
treatment the majority of persisting B cells expressed
CD55 and CD59, although the expression levels of CD55
(geometric mean fluorescence intensity) were significantly
lower on persisting lymphoid B cells in RA patients com-
pared with baseline expression (P= 0.049; Fig. 3A).
Expression levels of CD55 and CD59 on B cells were vari-
able before and after rituximab treatment. There was no
correlation between the expression levels of CD55 or
CD59 at baseline or after treatment and the frequencies
of B cell subsets after rituximab treatment or the extent of
B cell depletion (data not shown).
There were no significant differences in the frequency of
BAFF-R+ or TACI+ lymphoid B cells between RA patients
and HCs (Fig. 3B). BAFF-R is expressed on all B cell sub-
sets. There was no correlation between the level of ex-
pression and B cell subset frequencies. Since TACI is
mainly expressed on mature B cells and memory B
cells, we investigated the possible relationship between
the frequency of memory B cells and TACI+ B cells.
Indeed, the frequency of TACI+ B cells in RA patients at
baseline positively correlated with the frequency of
unswitched memory B cells (P= 0.01, r= 0.75) switched
memory (CD27+IgD) B cells (P= 0.005, r= 0.78) and
double negative (CD27IgD) B cells (P= 0.04, r= 0.64;
Fig. 3B) but not with naı¨ve B cells (Supplementary Fig.
S1, available at Rheumatology online). After rituximab
treatment the frequency of BAFF-R+ B cells significantly
decreased (median decreased from 92.968.1% of total B
cells; P= 0.03) while the frequency of TACI+ B cells within
the total B cell population was unaltered, although the
fraction of TACI+ B cells was numerically slightly higher
[median 47% (interquartile range 3361%) before to 54%
(4267%) after treatment P= 0.2; Fig. 3B].
Baseline expression of CD20, CD55, CD59, BAFF-R or
TACI and changes in expression after rituximab treatment
(CD20, CD55, CD59, BAFF-R or TACI) did not
correlate with DAS28 at 24 weeks (data not shown). An
important limitation of this exploratory part of the analysis
was that there were only three non-responders in the
whole study, and for this part of the analysis two of
FIG. 2 Immunohistochemical analysis of CD22 and CD138 staining in lymphoid tissue of RA patients
(A) Representative images of CD22 (B cells) and CD138 (plasma cells) staining before and after two rituximab infusions.
(B) The staining was quantified as positive cells per mm2. RTX: rituximab.
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these non-responders could not be analysed because of
low cell numbers.
Taken together, we found no indication of involvement
of low CD20 expression, complement inhibitor expression
levels or receptors for survival factors in resistance of LN
B cells to rituximab. In addition, expression of these fac-
tors on the total LN B cell population was not related to
clinical response, although these results need to be inter-
preted with caution.
Numbers of activated T cells are increased in
lymphoid tissue of RA patients and early activation
markers decrease after rituximab treatment
Therapeutic B cell depletion may diminish disease activity
through various mechanisms [23]. Besides reducing the pres-
ence of excreted B cell products such as cytokines, autoanti-
bodies and free light chains, T cell activation may be reduced,
specifically at sites of antigen presentation [24]. Therefore, we
analysed the activation status of T cells based on expression
of CD69 (marker for very early activation and tissue residence
[25]), CD25 (early activation) and HLA-DR (mid to late activa-
tion). Frequencies of tissue resident and early activated, tissue
resident T cells, CD3+CD69+ and CD3+CD25+CD69+, were
increased in RA patients compared with HCs (P=0.01 and
P=0.02, respectively, Fig. 4A) while total CD3+ T cell frequen-
cies were comparable. Furthermore, in contrast to HCs, the
frequency of activated T cells in RA at baseline positively
correlated with the frequency of switched memory B cells at
baseline (CD3+CD69+; P=0.02, r=0.65: CD3+CD25+;
P=0.01, r=0.69: CD3+CD25+CD69+ (P=0.002, r=0.80) but
not with the frequency of naı¨ve, unswitched or double nega-
tive B cells (Fig. 4A). After rituximab treatment the frequencies
of total CD3+, CD3+CD69+, CD3+CD25+ and CD3+HLA-DR+ T
cells were not altered. However, the frequency of activated
CD3+CD25+CD69+ T cells significantly decreased (P=0.03)
(changes in different T cell subsets are summarized in
Table 2). The baseline or post-treatment frequencies of acti-
vated T cells did not correlate to treatment response (data not
shown). Since circulating T cells may carry CD20 at low ex-
pression levels on their surface, we analysed CD20 expression
on LN CD3+ T cells at baseline and found that 99% of the
CD3+ T cells expressing CD69 are negative for CD20 (data not
shown) suggesting that the observed decrease in activated T
cells is not a direct effect of rituximab on CD20+ T cells but
rather an indirect consequence of B cell depletion. Based on
histology, the distribution and number of CD3+ T cells in
lymphoid tissue was unaltered after rituximab treatment
(Fig. 4B). As an indication for follicular T cell activity, we ana-
lysed the relative quantity of IL-21 mRNA in whole LN biopsies
from HCs and RA patients. IL-21 mRNA levels were higher in
LN biopsies from RA patients compared with HCs (P=0.004).
After rituximab treatment, IL-21 mRNA levels remained stable.
Taken together, these data show that in lymphoid tissue,
T cell activation is increased in RA patients and related to
switched memory B cell frequencies. The frequency of
early activated, tissue resident T cells is decreased after
rituximab treatment, but late activated T cells persist. In
addition, total IL-21 mRNA levels in LN biopsies from RA
patients remain high after rituximab treatment.
Discussion
The results presented here show for the first time that on
group level the distribution of naı¨ve and memory B cell
FIG. 3 Lymphoid B cell subsets expressing complement inhibitors and survival receptors
(A) Frequencies of CD19+ B cells positive for CD55 or CD59 and expression levels (gMFI) were analysed in healthy
individuals (HC; n= 5), RA patients (RA; n= 12) and RA patients after two rituximab infusions (RA post-RTX; n= 12).
(B) Frequencies of CD19BAFF-R+ B cells and CD19TACI+ B cells were analysed in the three study groups (HC; n= 5, RA;
n= 10). For CD19TACI+ B cells the correlations with switched memory B cells (CD27+IgD) and double negative B cells
(CD27IgD) at baseline are shown (n= 11). BAFF-R: B cell activating factor receptor; gMFI: geometric mean fluores-
cence intensity; HC: healthy controls; RTX: rituximab; TACI: transmembrane activator and CAML interactor.
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subsets in lymphoid tissue of RA patients is comparable
to the distribution observed in healthy individuals, while
the frequencies of CD21+CD23+IgDhighIgMvariable follicular
B cells that have been associated with active arthritis [19]
are increased. Furthermore, the frequencies of early acti-
vated, tissue resident T cells are significantly increased in
RA and related to the frequencies of lymphoid switched
memory B cells. Rituximab treatment depletes IgD+ naı¨ve,
unswitched memory (a mixture of germinal centre derived
and splenic marginal zone derived memory B cells) and
CD21+CD23+IgDhighIgMvariable follicular B cells, while B
cell follicular structures and switched memory B cells per-
sist. Of interest, rituximab treatment is also associated
with a significant decrease in the frequency of early acti-
vated, tissue resident CD3+CD25+CD69+ T cells, while
markers of persistent T cell activation were unaffected.
FIG. 4 Lymphoid T cell subsets; activation and relation with B cell subsets
A B
(A) Frequencies of LN T cell subsets (CD3CD69+, CD3CD25+, CD3CD25+CD69+ and CD3HLA-DR+) were analysed in
healthy individuals (HC; n= 5), RA patients (RA; n= 12) and RA patients after two rituximab infusions (RA post-RTX;
n= 12). The correlation of different T cell subsets in LN of RA patients at baseline with the frequency of switched memory
B cells are plotted on the right. (B) The amount of CD3+ T cells per mm2 of lymphoid tissue in RA patients before and after
rituximab treatment was analysed with immunohistochemistry staining and digital image analysis. Representative images
of CD3 staining are shown. Relative quantity of total IL-21 mRNA was analysed with qPCR in LN biopsies of healthy
individuals (HC; n= 5), RA patients (RA; n= 15) and RA patients after two rituximab infusions (RA post-RTX; n= 15). HC:
healthy controls; LN: lymph node; RTX: rituximab.
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Rituximab treatment induces clinical improvement in the
majority of autoantibody positive RA patients, but all pa-
tients eventually relapse [26]. We postulate that this may
be explained by persistence of autoreactive switched
memory B cells in secondary lymphoid tissues.
Previous studies have shown that rituximab causes
almost complete depletion of B cells in peripheral
blood, but only partial depletion in synovium [10, 11,
27] and bone marrow [9, 12]. Residual B cells in blood
mainly consist of memory B cells with an activated
phenotype [27]. Blood biomarker candidates like
IgJhiFCRL5lo for CD20-negative plasmablasts and a
higher ratio of memory B cells to transitional B cells at
reconstitution have been described to predict the re-
sponse to rituximab [28, 29]. However, understanding
which B cell subsets persist in tissues may provide
more insight into the mechanism of action of rituximab
in peripheral tissues and B cell repopulation after treat-
ment. Here we show that, similar to what has been
observed in blood, switched memory B cells and B cell
follicular structures persist in lymphoid tissue after ritux-
imab treatment. This indicates that rituximab leads to
varying levels of B cell depletion in different body com-
partments probably due to specific tissue microenviron-
ment factors [30]. In addition, it has previously been
shown that serum BAFF (B lymphocyte stimulator)
levels rise following B cell depletion [26]. BAFF binding
to BAFF-R may regulate B cell as well as plasma cell
survival in the context of autoimmunity [31] and is likely
to contribute to persistence of autoreactive B lineage
cells. Of the BAFF targeting cells, we found that TACI+
B cells persist in lymphoid tissue while the frequency of
BAFF-R+ B cells is decreased after rituximab treatment.
TACI is mainly expressed on resting memory B cells
while BAFF-R is expressed by all B cells including
naı¨ve B cells [32], which are the first B cells to repopu-
late in peripheral blood after rituximab treatment [33].
BAFF is constitutively produced by lymphoid stromal
cells [34] and can drive B cell differentiation of the re-
sidual lymphoid naı¨ve B cells expressing BAFF-R. BAFF
signalling through the BAFF receptor and TACI receptor
has been found especially important for naı¨ve B cell sur-
vival. In this context, anti-BAFF treatment in patients
with systemic lupus erythematosus has recently been
associated with rapid and strong effects on naı¨ve B
cells and a delayed decrease in autoreactivity-asso-
ciated B cells [35]. Co-operation of BAFF with other B
cell survival factors may mediate memory B cell survival.
Of interest, IL-21 has been shown to collaborate with
BAFF in stimulating T cell-independent plasmablast for-
mation from memory B cells in an experimental lupus
model [36]. In another experimental lupus model, IL-15
stimulated memory B cell survival together with BAFF
[37]. Taken together, the literature suggests that BAFF
may be an important candidate for the B cell survival
observed in the present study, as well as in the repopu-
lation after rituximab treatment.
There is also a role for T cell-dependent activation of B
cells in the pathogenesis of RA. Human synovium-SCID
mouse chimeras [24] showed that T cell activation in RA
synovium is B cell dependent and that T cells are involved
in the formation of tertiary lymphoid structures in the
inflamed tissue [38]. Consistent with this notion, we here
show an increased frequency of activated LN T cells in RA
patients correlating with the frequencies of switched
memory B cells. In addition, we showed an increased fre-
quency of a follicular B cell subset in RA patients, which is
mainly involved in T cell-dependent immune responses
and has been associated with active arthritis [19]. After
B cell depleting treatment, a decreased frequency of
markers of early T cell activation and a decrease in
these follicular B cells was observed in LNs, but in the
context of persistent late T cell activation. IL-21 mRNA
levels were markedly increased in lymphoid tissue of RA
patients but unaltered after rituximab treatment. IL-21 is
mainly produced by follicular T helper cells and is crucial
in providing signals for B cell proliferation and differenti-
ation [39]. Persistent levels of IL-21, presumably produced
by persistent follicular T helper cells, may provide positive
signals for B cell repopulation in secondary lymphoid
tissue. An effect of rituximab on activated T cells has
been described in SLE where clinical remission was asso-
ciated with decreased frequencies of activated T helper
cells in peripheral blood [40]. A recent study analysed LN
B cell persistence after CD20-mediated B cell depletion in
experimental encephalomyelitis mouse models [41]. LN
memory B cells persisted to some extent in naı¨ve mice.
In mice induced with a TB cell-dependent form of experi-
mental encephalomyelitis, an enhanced number of auto-
reactive memory B cells persisted in LNs. Clinical relapse
was associated with enhanced expansions of these cells
within an overall restricted B cell repertoire. This indicates
that factors involved in LN TB cell crosstalk are likely to
be involved in both the clinical response to rituximab and
clinical relapses after rituximab. In future research studies
in LN biopsies, it will be of importance to investigate in
more detail germinal centre B cells and Tfh cells, as well
as factors produced by the LN microenvironment support-
ing this BT cell crosstalk.
This is the first report describing the lymphoid tissue
response to rituximab in RA patients; the results are con-
sistent with and extend a previous report in four patients
showing that a single dose of rituximab results in incom-
plete depletion of B cells in iliac LNs of patients receiving
renal transplantation [42]. Similarly, there was persistence
of B cells in LNs of a subset of cynomolgus monkeys
treated with rituximab in a model of allotransplantation
[43]. The results support the view that rituximab treatment
improves RA in part because, next to B cell depletion, it
results in decreased T cell activation. The observed per-
sistence of switched memory B cells in lymphoid tissues
after treatment may explain the observation that this ther-
apy does not result in a cure for RA.
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